**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 88532

**Manuscript Type:** CASE REPORT

**Clinical experience sharing on gastric microneuroendocrine tumors: A case report**

Wang YJ *et al*. Clinical experience sharing on gastric microneuroendocrine tumors

You-Jun Wang, Da-Ming Fan, Yu-Shuang Xu, Qi Zhao, Zhen-Fang Li

**You-Jun Wang, Qi Zhao, Zhen-Fang Li,** Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, Shandong Province, China

**Da-Ming Fan,** Department of Pathology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, Shandong Province, China

**Yu-Shuang Xu,** Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China

**Author contributions:** Wang YJ contributed to manuscript writing and editing, and data collection; Fan DM and Xu YS contributed to data analysis; Zhao Q and Li ZF contributed to conceptualization and supervision; and all authors contributed to writing of the manuscript.

**Corresponding author: Zhen-Fang Li, MM, Chief Physician, Doctor,** Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Jinan 250000, Shandong Province, China. klyjr@sina.com

**Received:** September 27, 2023

**Revised:** December 14, 2023

**Accepted:** January 10, 2024

**Published online:**

**Abstract**

BACKGROUND

The majority of gastric neuroendocrine tumors (G-NENs) are present in various lesions under endoscopy, and they can be polypoid uplifts, submucosal tumors or papules, erosions, and ulcers. The lesions are mostly confined to the mucosal or submucosal layer, usually less than 2 cm, and exclusively localized to the gastric body or fundus. In type 1 G-NENs, about 22% of cases have no visible lesions under an endoscope, and such lesions can only be detected *via* biopsies (microcarcinoids).

CASE SUMMARY

A 67-year-old female patient with appetite loss for more than half a year and personal history of hyperthyroidism was admitted to our hospital. After admission, a random multi-point biopsy was performed on the gastric body, fundus, angle, and antrum through gastroscopy. Pathological examination showed chronic severe atrophic gastritis in the fundus and body of the stomach. The small curvature of the gastric body, the anterior wall of the gastric body, and the posterior wall of the gastric body displayed proliferation of intestinal chromaffin cells. The curvature of the gastric body showed neuroendocrine tumor G1 (carcinoid), while the antrum and angle of the stomach showed mild atrophic gastritis with mild intestinal metaplasia. Immunohistochemical examination showed that the greater curvature of the gastric body was Syn (+), CgA (+), and Ki-67 (+, approximately 1%), which is consistent with neuroendocrine tumors (grade 1). Regular gastroscopy and biopsy should be performed every one to two years to monitor G-NENs.

CONCLUSION

In the case under study, the patient did not have any visible raised lesions under a gastroscope, and the lesions were found only after a random biopsy. This article combines the endoscopic manifestations and clinical features of the lesions in this case to improve the diagnosis of G-NENs.

**Key Words:** Neuroendocrine tumor; Micro carcinoids; Endoscopy; Case report

Wang YJ, Fan DM, Xu YS, Zhao Q, Li ZF. Clinical experience sharing on gastric microneuroendocrine tumors: A case report. *World J Clin Cases* 2024; In press

**Core Tip:** Gastric neuroendocrine tumor (G-NEN) is a group of rare tumors originating from neuroendocrine cells in the stomach. Especially in type 1 G-NEN, some cases have no visible lesions under endoscopy, and these lesions can only be detected *via* biopsies (microcarcinoids). Therefore, it is particularly important to correctly identify and diagnose diseases. This article reports a case of a 67-year-old female patient with gastric microneuroendocrine tumors, and reviews relevant literature to better identify and diagnose gastric microneuroendocrine tumors.

**INTRODUCTION**

Gastric neuroendocrine tumor (G-NEN) is a group of rare tumors originating from neuroendocrine cells in the stomach. However, with the development of endoscopic technology and the improvement of clinical understanding of diseases, more and more G-NEN has been found, and the incidence rate is increasing year by year. For different types of G-NEN, it is necessary to fully understand and master the endoscopic manifestations based on different background diseases, cell origins, and pathogenesis, in order to diagnose and differentiate.

In the case under study, the patient did not have any visible raised lesions under a gastroscope, and the lesions were found only after a random biopsy. By studying this case and reviewing relevant literature, we believe that endoscopists should improve their understanding of the endoscopic manifestations of G-NENs, especially in the identification of small lesions. Gastroscopic examination should be closely combined with the patient’s medical history and clinical characteristics and carefully standardized. For patients at risk of developing G-NENs (such as patients with chronic atrophic gastritis who test negative for *Helicobacter pylori* (*H. pylori*) and have a dominant gastric body or patients with autoimmune gastritis and a medical history of more than two years), even though no visible protruding lesions are observed under an endoscope, random multipoint biopsy should be performed (especially on the four walls of the gastric body) to improve the positive rate of G-NEN diagnosis.

**CASE PRESENTATION**

***Chief complaints***

A 67-year-old female patient with appetite loss for more than half a year and personal history of hyperthyroidism was admitted to our hospital.

***History of present illness***

The patient suffered chronic anemia.

***History of past illness***

The patient has a history of chronic anemia and has not been treated.

***Personal and family history***

The patient denies any family history of anemia and tumors.

***Physical examination***

On physical examination, the vital signs were as follows: Body temperature, 36.3 °C; blood pressure, 121/73 mmHg; heart rate, 84 beats per min; respiratory rate, 18 breaths per min. Furthermore, the patient has anemic appearance and pale skin mucosa.

***Laboratory examinations***

Auxiliary examination after admission revealed the following: Hemoglobin = 69 g/L, mean corpuscular volume = 119 fL, vitamin B12 < 50 pg/mL, folic acid = 32.5 ng/mL, ferritin = 208.9 ng/mL, parietal cell antibody was negative, internal factor antibody was positive, gastrin 17 = 97.1 pmol/L (1.7-7.6 pmol/L), pepsinogen I/pepsinogen II = 2.17, C13 urea breath test was negative, and serum *H. pylori* antibody was negative.

***Imaging examinations***

Whole-body imaging procedures (computed tomography scan and abdominal ultrasonography) did not reveal metastatic involvement of any other organ.

***Further diagnostic work-up***

Gastroscopy was performed after admission and showed that the gastric body and fundus mucosa were thinned, red, and white (but mainly white). The submucosal vascular network was transparent, and the gastric antrum mucosa was normal (Figure 1). The diagnosis was chronic atrophic gastritis. In order to clarify the type of atrophic gastritis, random multipoint biopsies were performed on the gastric body, fundus, angle, and antrum. Pathological examination showed that the gastric fundus and gastric body had chronic severe atrophic gastritis. The lesser curvature of the gastric body, the anterior wall of the gastric body, and the posterior wall of the gastric body exhibited hyperplasia of enterochromaffin cells. The greater curvature of the gastric body showed neuroendocrine tumor G1 (carcinoid), and the gastric antrum and gastric angle exhibited mild atrophic gastritis with mild intestinal epithelial metaplasia. Immunohistochemical examination revealed that the greater curvature of the gastric body was Syn (+), CgA (+), and Ki-67 (+, about 1%), which is consistent with neuroendocrine tumors (Grade 1; Figure 2).

**FINAL DIAGNOSIS**

Based on the patient’s medical history, clinical manifestations, laboratory examinations, and gastroscopy pathological results, we ultimately diagnosed the case as type 1 G-NENs grade G1 and autoimmune gastritis.

**TREATMENT**

Regular gastroscopy and biopsy should be performed every one to two years to monitor G-NENs. The patient also suffers from pernicious anemia. After being diagnosed upon admission, she has been taking oral vitamin B12 and folic acid, and have undergone regular blood routine checkups.

**DISCUSSION**

G-NENs can be classified into three types on the basis of the 2016 European Neuroendocrine Tumor Society (ENETS) guidelines (Table 1)[1]. Type 1 G-NENs are common in women, usually G1 level, and rarely metastasize[2]. The background mucosa of autoimmune gastritis should be identified first. Under white light endoscopy, it appears as extensive atrophy of the gastric fundus and body, and the gastric antrum has a normal mucosa and can be accompanied with atrophy[3]. Atrophic mucosa can be seen *via* magnifying narrowband imaging endoscopy (ME-NBI); it has tightly arranged small circular and oval pores surrounded by a network of capillaries[4]. It is considerably different from the granular or papillary atrophy caused by *H. pylori* infection. In this context, multiple different phenotypes of protruding lesions, including residual gastric fundus glands, proliferative polyps, early gastric cancer, and type I g-NET, often occur[3], and endoscopists should learn to recognize and differentiate them. Typical type I g-NET often presents as submucosal protrusion lesions with a yellow or red color under white light endoscopy and sometimes a central depression[5,6]. NBI shows a light-brown area, and ME-NBI shows a cyan, spiral-shaped, abnormally dilated subepithelial blood vessel in the white area, which is dilated like a gyrus[6]. This ME-NBI endoscopic appearance needs to be differentiated from gastric fundus adenocarcinoma, which often occurs in a nonatrophic, *H. pylori-*negative, gastric mucosa background with a single submucosal protuberant lesion. Endoscopists can easily diagnose G-NENs *via* biopsy pathology and immunohistochemistry as long as suspected lesions are found through endoscopy. However, for type 1 G-NENs, about 22% of cases have no visible lesions under an endoscope, and only through blind examination of the stomach body and fundus can the lesions be found under a microscope[7]. In the case presented in this study, the patient did not have any obvious gastrointestinal discomfort symptoms, and no visible raised lesions were found under an endoscope. Under ordinary white light gastroscopy, this case was manifested as chronic atrophic gastritis. If the endoscopist had not performed random biopsy at the time, the G-NENs would have been missed in the diagnosis.

Given the inert growth of type 1 G-NENs, the lesions can be followed up for a long time. Researchers recommend the use of biopsy forceps to remove all visible lesions and endoscopic mucosal resection for lesions greater than 5 mm[8]. ENETS guidelines recommend that for tumors ≥ 1 cm, endoscopic resection can be considered, and preoperative endoscopic ultrasound examination is required to assess the risk of metastasis. The patient in this case did not have any visible elevated lesions under a gastroscope, so regular follow-up with gastroscopy and biopsy every 1-2 years is recommended.

**CONCLUSION**

In summary, by studying this case and reviewing relevant literature, we believe that endoscopists should improve their understanding of the endoscopic manifestations of G-NENs, especially in the identification of small lesions. Gastroscopic examination should be closely combined with the patient’s medical history and clinical characteristics and carefully standardized. For patients at risk of developing G-NENs (such as patients with chronic atrophic gastritis who test negative for *H. pylori* and have a dominant gastric body or patients with autoimmune gastritis and a medical history of more than two years), even though no visible protruding lesions are observed under an endoscope, random multipoint biopsy should be performed (especially on the four walls of the gastric body) to improve the positive rate of GNEN diagnosis. For patients with a clear diagnosis of gastric microneuroendocrine tumors, magnifying gastroscopy coupled with NBI and endoscopic staining can be performed during long-term endoscopic follow-up to avoid missing gastric microlesions.

**REFERENCES**

1 **Delle Fave G**, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. *Neuroendocrinology* 2016; **103**: 119-124 [PMID: 26784901 DOI: 10.1159/000443168]

2 **Shah MH**, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021; **19**: 839-868 [PMID: 34340212 DOI: 10.6004/jnccn.2021.0032]

3 **Terao S**, Suzuki S, Yaita H, Kurahara K, Shunto J, Furuta T, Maruyama Y, Ito M, Kamada T, Aoki R, Inoue K, Manabe N, Haruma K. Multicenter study of autoimmune gastritis in Japan: Clinical and endoscopic characteristics. *Dig Endosc* 2020; **32**: 364-372 [PMID: 31368581 DOI: 10.1111/den.13500]

4 **Yagi K**, Nakamura A, Sekine A, Graham D. Features of the atrophic corpus mucosa in three cases of autoimmune gastritis revealed by magnifying endoscopy. *Case Rep Med* 2012; **2012**: 368160 [PMID: 22811721 DOI: 10.1155/2012/368160]

5 **Ichikawa J**, Tanabe S, Koizumi W, Kida Y, Imaizumi H, Kida M, Saigenji K, Mitomi H. Endoscopic mucosal resection in the management of gastric carcinoid tumors. *Endoscopy* 2003; **35**: 203-206 [PMID: 12584637 DOI: 10.1055/s-2003-37256]

6 **Sato Y**. Endoscopic diagnosis and management of type I neuroendocrine tumors. *World J Gastrointest Endosc* 2015; **7**: 346-353 [PMID: 25901213 DOI: 10.4253/wjge.v7.i4.346]

7 **Kaltsas G**, Grozinsky-Glasberg S, Alexandraki KI, Thomas D, Tsolakis AV, Gross D, Grossman AB. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. *Clin Endocrinol (Oxf)* 2014; **81**: 157-168 [PMID: 24750249 DOI: 10.1111/cen.12476]

8 **Yang Z**, Wang W, Lu J, Pan G, Pan Z, Chen Q, Liu W, Zhao Y. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival. *Cell Physiol Biochem* 2018; **45**: 389-396 [PMID: 29402806 DOI: 10.1159/000486915]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patients for the publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 27, 2023

**First decision:** December 7, 2023

**Article in press:**

**Specialty type:** Gastroenterology & hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Cerwenka H, Austria; Taheri S, Iran **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**

**Figure Legends**







**Figure 1 Gastroscopy in a patient with gastric microneuroendocrine neoplasms.** The gastric body and fundus mucosa were obviously thinned, red and white, mainly white, the submucosal vascular network was transparent, and the gastric antrum mucosa was normal.A: Upper part of the greater curvature of the stomach; B: The lower part of the greater curvature of the stomach; C: The posterior wall of the lesser curvature of the gastric body; D: Gastric angle; E: Gastric fundus; F: Gastric antrum.





**Figure 2 Pathological and immunohistochemical examination of the greater curvature of the gastric body.** A: Hematoxylin and eosin mucosal tissue atrophy, lamina propria oxyntic glands disappeared, replaced by incomplete intestinal metaplasia glands and pseudopyloric glands, local mucosal lamina propria showed loss of proper glands, replaced by epithelioid/spindle-like cells nest; B: Ki-67 (+, about 1%); C: CgA (+); D: Syn (+).

**Table 1 Classification of gastric neuroendocrine neoplasms on the basis of the 2016 European Neuroendocrine Tumor Society guidelines**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Type 1** | **Type 2** | **Type 3** |
| Proportion among G-NENs, % | 70-80 | 5-6 | 14-25 |
| Tumor characteristics | Often small (< 1-2 cm), multiple in 65% of cases, polypoid in 78% of cases | Often small (< 1-2 cm) and multiple, polypoid | Unique, often large (> 2 cm) polypoid and ulcerated |
| Associated conditions | Atrophic body, gastritis | Gastrinoma/MEN-1 | None |
| Pathology | NET G1-G2 | NET G1-G2 | NET G3 |
| Serum gastrin levels | ↑ | ↑ | Normal |
| Gastric pH | ↑ | ↓ | Normal |
| Metastases, % | 2-5 | 10-30 | 50-100 |
| Tumor-relateddeaths, % | 0 | < 10 | 25-30 |

G-NENs: Gastric neuroendocrine tumors; NET: Neuroendocrine tumor; MEN-1: Multiple endocrine neoplasia type 1.